Tech Transfer Roundup: Aduro Hopes Stanford Algorithm Will Optimize Its IO Candidates
Aduro Biotech discusses what it looks for in an academic collaboration. Plus, Sarepta adds gene therapies to its Duchenne pipeline from Nationwide Children's Hospital and Columbia University out-licenses IP to a pair of biotechs.
You may also be interested in...
Finance Watch: Ayala Launches First Biopharma IPO In May
The cancer drug developer raised $55m. Also, Lyra raised $56m in the last of four biopharma IPOs in April, Biogen sold $3bn worth of debt, Oberland raised a $1.05bn fund and Praxis launched with more than $100m.
Aduro Says End Of Janssen Collaborations “Not A Lethal Blow”
Both Janssen and Aduro gradually realized the Listeria technology platform was not delivering hoped-for results. Aduro will not continue the projects abandoned by Janssen, and will focus on its STING and APRIL programs going forward.
Keeping Track: Tpoxx Wins Green Light For Smallpox, Submissions Galore, And A Broader Approval For Xtandi
The latest drug development news and highlights from our US FDA Performance Tracker.